Linq ii¿ insertable cardiac monitor: FDA malfunction report involving AI
The FDA received a malfunction report involving Linq ii¿ insertable cardiac monitor, made by Medtronic singapore operations. It was reported that true pause episodes were rejected as false by the artificial intelligence (ai) algorithm. it was further reported that the implantable cardiac monitor (icm) detected false ventricular tachycardia (vt) episodes. the icm remains in use. no patient complications have been reported as a result of this event.

"Onassis Cardiac Surgery Center, Athens, Greece" by Tilemahos Efthimiadis is licensed under CC BY 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/2.0/.
- Device: Linq ii¿ insertable cardiac monitor; manufacturer: Medtronic singapore operations.
- FDA report type: Malfunction.
- An adverse-event report is a safety signal, not proof that the device caused the event.
An FDA adverse-event report linked Linq ii¿ insertable cardiac monitor to an AI-related malfunction; the report requires investigation and does not by itself establish causality.
The rundown
It was reported that true pause episodes were rejected as false by the artificial intelligence (ai) algorithm. it was further reported that the implantable cardiac monitor (icm) detected false ventricular tachycardia (vt) episodes. the icm remains in use. no patient complications have been reported as a result of this event.
The report is part of FDA’s MAUDE surveillance data. It should be read as a signal for follow-up, not a clinical conclusion or a verified incidence rate.
Sources
- GovernmentFDA MAUDE report 250936882026-05-06
The debate